Challenges in IBD Research: Novel Technologies
Manish Dhyani(Lahey Medical Center), Fabrizio Michelassi(NewYork–Presbyterian Hospital), Nitin Joshi(Brigham and Women's Hospital), D. Brent Polk(University of California San Diego), Nataly Shtraizent(Icahn School of Medicine at Mount Sinai), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai), Jeffrey M. Karp(Broad Institute), Timothy K. Lu(Massachusetts Institute of Technology), Giovanni Traverso(Broad Institute), Jonathan Braun(Cedars-Sinai Medical Center), Gerard Honig(Crohn's and Colitis Foundation), Andres Hurtado‐Lorenzo(Crohn's and Colitis Foundation), Mark Donowitz(Johns Hopkins University), Willem A. Bemelman(Vrije Universiteit Amsterdam), Vijay Yajnik(Massachusetts General Hospital), Gustavo Mostoslavsky(Boston University), Ashley N. Guillory(The University of Texas Medical Branch at Galveston), Michael S. Gee(Harvard University), Conor P. Delaney(Cleveland Clinic), Dan Peer(Tel Aviv University), María Del Mar Mañú Pereira(Vall d'Hebron Institut de Recerca), André D’Hoore, Heiko G. Niessen(Boehringer Ingelheim (Germany)), Neil Lineberry(Institute for Learning and Development)
Cited by 26
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k